3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Azacitidine
66
venetoclax
21
Decitabine
16
Cytarabine
12
decitabine and cedazuridine drug combination
10
AP 1903 reagent
10
Cyclophosphamide
7
fludarabine
6
pevonedistat
5
mocetinostat
5
ON 01910
5
Busulfan
5
treosulfan
4
sabatolimab
4
ruxolitinib
4
cedazuridine
4
cc-486
4
Mycophenolic Acid
4
Lenalidomide
4
Injections
4
plerixafor
3
luspatercept
3
imetelstat
3
glasdegib
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Methotrexate
3
GRN163L peptide
3
Clofarabine
3
CPX-351
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myelodysplastic Syndromes
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled